ProQR Shareholders Approve Key Resolutions at Annual Meeting

The latest announcement is out from ProQR ( (PRQR) ).

On June 3, 2025, ProQR Therapeutics N.V. held its annual general meeting of shareholders in Amsterdam, where several key resolutions were passed. Shareholders approved the adoption of the 2024 annual accounts, released board members from liability for the year, and re-appointed James Shannon and Daniel de Boer to the board. Additionally, KPMG Accountants N.V. was appointed as the external auditor for 2026, and the board was authorized to issue and acquire ordinary shares. These decisions reflect strong shareholder support and are expected to enhance ProQR’s governance and operational capabilities.

The most recent analyst rating on (PRQR) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on ProQR stock, see the PRQR Stock Forecast page.

Spark’s Take on PRQR Stock

According to Spark, TipRanks’ AI Analyst, PRQR is a Neutral.

ProQR’s overall stock score reflects significant challenges in achieving profitability and positive cash flow, despite strong revenue growth. The technical indicators provide some short-term bullish signals, but the longer-term trends remain bearish. The negative P/E ratio highlights valuation difficulties due to ongoing losses, and the absence of a dividend yield limits attractiveness for income investors.

To see Spark’s full report on PRQR stock, click here.

More about ProQR

ProQR Therapeutics N.V. operates in the biotechnology industry, focusing on the development of RNA therapies for genetic eye diseases. The company is dedicated to creating transformative treatments that address unmet medical needs, particularly in the field of ophthalmology.

Average Trading Volume: 607,226

Technical Sentiment Signal: Sell

Current Market Cap: $187.3M

Learn more about PRQR stock on TipRanks’ Stock Analysis page.